L-Canavanine modulates cellular growth, chemosensitivity and P-glycoprotein substrate accumulation in cultured human

D R Worthen1, L Chien, C P Tsuboi

  • 1Division of Medicinal Chemistry and Pharmaceutics, College of Pharmacy, University of Kentucky, Lexington 40536, USA.

Cancer Letters
|July 9, 1999
PubMed

Insights

L-Canavanine (L-CAV) shows equal cytotoxicity against parental and multi-drug resistant (MDR) tumor cells. Pre-treatment with L-CAV sensitizes cancer cells to chemotherapy drugs, suggesting its potential as a chemosensitizer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • L-Canavanine (L-CAV), an L-arginine analog, is known to induce non-functional proteins and exhibit cytotoxicity in human tumor cells.
  • Multi-drug resistance (MDR) in cancer is a significant challenge, often mediated by efflux pumps like P-glycoprotein (P-gp).

Purpose of the Study:

  • To evaluate the cytotoxicity of L-CAV on both parental and MDR human tumor cell lines.
  • To investigate the effect of L-CAV on P-glycoprotein (P-gp) expression, activity, and substrate accumulation.
  • To assess the chemosensitization potential of L-CAV when combined with standard antineoplastic agents.

Main Methods:

  • Cytotoxicity was assessed using MTT assays.
  • Cellular accumulation of P-gp substrates was measured.
  • The effect of L-CAV on P-gp expression was determined by indirect immunofluorescence.
  • Chemosensitization potential was evaluated by pre-treating cells with L-CAV before exposure to chemotherapy drugs.

Main Results:

  • MDR tumor cells exhibited equal sensitivity to L-CAV as their parental counterparts.
  • L-CAV exposure did not alter P-gp expression but reduced P-gp substrate accumulation in cultured cells.
  • L-CAV pre-treatment significantly increased tumor cell sensitivity to doxorubicin, cisplatin, 5-fluorouracil, mitoxantrone, and bleomycin.

Conclusions:

  • L-CAV is equally cytotoxic to parental and MDR tumor cells and does not induce or act as a substrate for P-gp.
  • L-CAV demonstrates chemosensitizing properties, enhancing the efficacy of several DNA-targeting chemotherapy drugs.
  • L-CAV shows promise as a chemosensitizer to overcome drug resistance in cancer chemotherapy.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...